
Helical is focused on providing open-source bio foundation models, particularly in the realm of single-cell analysis, enabling scientists to leverage advanced AI tools for their research. Their platform offers a community-driven approach, allowing users to fine-tune and integrate these models into their workflows, thereby enhancing research capabilities in the biological sciences. With a commitment to accessibility and collaboration, Helical positions itself as a key player in the AI for bio sector, catering to researchers and developers looking for innovative solutions.

Helical is focused on providing open-source bio foundation models, particularly in the realm of single-cell analysis, enabling scientists to leverage advanced AI tools for their research. Their platform offers a community-driven approach, allowing users to fine-tune and integrate these models into their workflows, thereby enhancing research capabilities in the biological sciences. With a commitment to accessibility and collaboration, Helical positions itself as a key player in the AI for bio sector, catering to researchers and developers looking for innovative solutions.
What they do: Platform for Bio Foundation Models enabling in-silico experiments for drug discovery and R&D
HQ: Luxembourg
Stage / funding: Seed (closed Jun 28, 2024)
Founders: Mathieu Klop; Maxime Allard; Rick Schneider
| Company |
|---|
Drug discovery and pharmaceutical R&D using AI-driven in-silico experiments
2024
Biotechnology Research
Reported seed round with seven investors
“Has participation from early-stage investors and angel/backer set including Frst and named investors”
Drug discovery still relies on wet labs: slow, expensive, and constrained by physical trial-and-error. Helical is changing that.
We build the application layer that makes Bio Foundation Models usable in real-world drug discovery, enabling pharma and biotech teams to run millions of virtual experiments in days, not years. Today, leading global pharma companies already use Helical, and we’re at the start of a highly ambitious growth journey.
We’re a founder-led, talent-dense team building a category-defining company from Europe. We care deeply about the quality of our work, move fast, and expect ownership. If you’re excited by complexity, real responsibility, and shaping how a company actually operates as it scales, you’ll feel at home here.
At Helical, we’re focused on leveraging research to transform the future of drug discovery. We are seeking an Applied Research Engineer - Post-Training to join our team, focusing on maximizing the performance of cutting-edge foundation models in real-world applications.
You will own the full post-training lifecycle for biological foundation models—from alignment strategy to production deployment. This means designing and running pipelines that transform general-purpose models into therapeutic-specific tools for our pharma clients. You'll work directly with real drug discovery problems: adapting models to disease areas, cell types, and perturbation contexts that matter for target identification, hit discovery, and beyond.
This isn't a support role. You'll make core technical decisions about how we extract value from foundation models—what to fine-tune, how to validate it biologically, and how to ship it to customers who are running experiments that inform real clinical programs. You'll collaborate closely with our ML infrastructure and biology teams, but you'll be the person responsible for whether our post-training actually works.
Essentials
Bonus Points